Results 261 to 270 of about 1,196,134 (401)

Targeting NF-kappa B/proinflammatory cytokines/ TGF-β/ TIMP-1 pathway by crocin enhances recovery from hepatic fibrosis in rats. [PDF]

Sci Rep
Hassan MH, Salama SA, Ismail RS.
europepmc   +1 more source

Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation

Annals of Gastroenterological Surgery, EarlyView.
In a single‐center cohort of 577 adult LDLT recipients who underwent simultaneous splenectomy, clinically significant SFSS grade B/C (ILTS‐iLDLT‐LTSI 2023) occurred in 18.2% and was associated with inferior graft survival. Multivariate analysis identified MELD ≥ 30, NLR ≥ 4.5, and donor age ≥ 50 years as independent risk factors, which risk rising ...
Kyohei Yugawa, Takeo Toshima, Shinji Itoh, Takashi Motomura, Shohei Yoshiya, Norifumi Iseda, Tomoharu Yoshizumi   +6 more
wiley   +1 more source

Independent effects of Metformin and Dapagliflozin on Fetuin-A, hepatic and pancreatic fat, and hepatic fibrosis in Asian Indians with type 2 diabetes. [PDF]

Sci Rep
Dutta K, Bhatt SP, Ghosh A, Gupta R, Tyagi K, Ansari IA, Pandey S, Misra A.   +7 more
europepmc   +1 more source

Predicting Postresection Colorectal Liver Metastases Recurrence Using Advanced Graph Neural Networks with Explainability and Causal Inference

Advanced Intelligent Systems, EarlyView.
This study introduces a framework that combines graph neural networks with causal inference to forecast recurrence and uncover the clinical and pathological factors driving it. It further provides interpretability, validates risk factors via counterfactual and interventional analyses, and offers evidence‐based insights for treatment planning ...
Jubair Ahmed, Md. Abdur Rahman, Mohaimenul Azam Khan Raiaan, Sami Azam   +3 more
wiley   +1 more source

Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Int J Mol Sci
Motta BM, Rosati A, Festa M, Basile A, Sarcina T, Turco MC, Persico M.   +6 more
europepmc   +1 more source

Vitronectin deficiency attenuates hepatic fibrosis in a non‐alcoholic steatohepatitis‐induced mouse model

, 2019
Momoka Hayashida, Kei Hashimoto, Tomoko Ishikawa, Yasunori Miyamoto   +3 more
openalex   +2 more sources

Characterization of inflammatory pseudotumors in a large animal model of liver cancer

Animal Models and Experimental Medicine, EarlyView.
CT images in arterial and portal venous phases of liver lesions in Oncopig. Abstract Background The development of relevant and robust large animal models of hepatocellular carcinoma is needed to test new therapeutic strategies for this disease. Transgenic approaches hold promise in addressing this complex problem. One such model, the Oncopig, has been
Erik N. K. Cressman, Samantha Hicks, Natalie W. Fowlkes, Danielle L. Stolley, Maria Sophia Stenkamp   +4 more
wiley   +1 more source

Prevalence of Hepatic Fibrosis and Performance of Non-invasive Liver Fibrosis Scores in an Eastern Indian Diabetic Population with NAFLD. [PDF]

J ASEAN Fed Endocr Soc
Sanyal D, Chowdhury S, Goswami S, Dasgupta A, Chowdhury AS, Mondal S, Bhattacharyya S, Chowdhury SR, Sikdar M.   +8 more
europepmc   +1 more source

ChREBP refines the hepatic response to fructose to protect the liver from injury [PDF]

, 2017
Angela M. Hall, Brian N. Finck, Hetz, Montgomery   +3 more
core   +3 more sources

Two‐stage portal flow modulation for volume‐augmented grafts in living donor liver transplantation: Rat model validation

Animal Models and Experimental Medicine, EarlyView.
This study presents a two‐stage portal flow modulation strategy for graft procurement in living donor liver transplantation with the aim of expanding left lateral lobe grafts, thereby circumventing technical and anatomical limitations of conventional approaches.
Yuqi Gong, Yutong Chen, Zhoucheng Wang, Libin Dong, Zhengxing Lian, Kai Wang, Xiao Xu   +6 more
wiley   +1 more source